中國(guó)科學(xué)院院士

美國(guó)醫(yī)學(xué)與生物工程院（AIMBE）fellow

中國(guó)科學(xué)院過程工程研究所研究員

生化工程國(guó)家重點(diǎn)實(shí)驗(yàn)室主任

中國(guó)顆粒學(xué)會(huì)副理事長(zhǎng)

中國(guó)化學(xué)會(huì)會(huì)士

中國(guó)化工學(xué)會(huì)會(huì)士

中國(guó)微米納米技術(shù)學(xué)會(huì)會(huì)士

中國(guó)化工學(xué)會(huì)生物化工專業(yè)委員會(huì)副主任委員

中國(guó)生物工程學(xué)會(huì)生物基材料專業(yè)委員會(huì)主任委員

報(bào)告題目：新型分離介質(zhì)的制備和蛋白藥/疫苗純化應(yīng)用
Preparation of Novel Microspheres for Protein / Vaccine Separation Application
Polysaccharide particles such like agarose particles have been widely used in protein separation and purification as chromatographic packing materials by biological scientists and in industry. However, the limitation of conventional agarose particles is that the separation resolution is limited due to their broad size distribution. Furthermore, the particles with large size are usually used for industrial separation and purification to avoid the increase of back-pressure, which also limit the separation resolution. On the other hand, the particulate vaccine such like virus-like particle (VLP) has attracted more and more attention, conventional agarose particles with small pore size not only limited the adsorption of VLP, but also enhanced the disassociation of VLP, resulting very low activity recovery of VLP.We have developed a novel membrane process to prepare uniform agarose particle. By this technique we can control the CV (coefficient of variation) value which representing the size distribution around 15%, and we can prepare small uniform particles with high agarose concentration. Therefore, we can use small particles instead of large particles, and increase the separation resolution and flow rate of chromatography.  We have developed a new process to prepare giga-porous particle with pore size controllable between 100nm to 500 nm, and we found that it not only increased the loading amount of VLP, but also avoided the disassociation of VLP. This was because large pore size weakened the multi-site interaction between VLP and pore. This novel particle has been used for production of particulate vaccine instead of ultra-high speed centrifugation technique, much higher recovery was achieved.

個(gè)人簡(jiǎn)介
馬光輝，中國(guó)科學(xué)院院士，美國(guó)醫(yī)學(xué)與生物工程院（AIMBE）fellow，生化工程國(guó)家重點(diǎn)實(shí)驗(yàn)室主任。國(guó)家杰出青年獲得者，基金委創(chuàng)新群體首席，中國(guó)顆粒學(xué)會(huì)副理事長(zhǎng)，中國(guó)化學(xué)會(huì)會(huì)士、中國(guó)化工學(xué)會(huì)會(huì)士、中國(guó)微米納米技術(shù)學(xué)會(huì)會(huì)士、中國(guó)化工學(xué)會(huì)生物化工專業(yè)委員會(huì)副主任委員、中國(guó)生物工程學(xué)會(huì)生物基材料專業(yè)委員會(huì)主任委員。研究方向?yàn)榫簧镂⑶蚝臀⒛业闹苽浼捌湓谏こ毯歪t(yī)學(xué)工程中的應(yīng)用，研究和開發(fā)用于生化分離、藥物載體、免疫佐劑（疫苗遞送系統(tǒng)）、細(xì)胞培養(yǎng)微載體、酶固定化載體等創(chuàng)新產(chǎn)品。在Nat. Mater., Sci. Transl. Med., Nat. Nanotechnol., Nat. Biomed. Eng., Sci. Adv., Nat. Commun., JACS, Adv. Mater.等國(guó)際著名學(xué)術(shù)期刊上發(fā)表SCI論文500余篇。出版中英文專著12部，撰寫學(xué)術(shù)書章節(jié)22篇。中國(guó)發(fā)明專利授權(quán)81項(xiàng)，國(guó)際專利授權(quán)12項(xiàng)，專利技術(shù)和產(chǎn)品在國(guó)內(nèi)外500多家單位得到應(yīng)用。獲國(guó)家技術(shù)發(fā)明二等獎(jiǎng)、北京市科學(xué)技術(shù)一等獎(jiǎng)、中國(guó)化工學(xué)會(huì)科學(xué)技術(shù)獎(jiǎng)基礎(chǔ)研究成果獎(jiǎng)一等獎(jiǎng)、中國(guó)顆粒學(xué)會(huì)自然科學(xué)獎(jiǎng)一等獎(jiǎng)、中國(guó)石油和化學(xué)工業(yè)聯(lián)合會(huì)技術(shù)發(fā)明一等獎(jiǎng)、侯德榜化工科技創(chuàng)新獎(jiǎng)、“中國(guó)科協(xié)全國(guó)優(yōu)秀科技工作者”稱號(hào)。